Research
-
Pharmaceutical giant Novo Nordisk working on developing glucose responsive insulins.
A graduate who co-founded a company while studying at university could become a multi-millionaire after it was sold in a deal potentially worth £623m. Dr Harry Destecroix, 31, co-founded Ziylo while studying for his PhD at the University of Bristol four years ago. It created a new technology which can be developed to treat diabetes more effectively. Pharmaceutical giant Novo Nordisk’s purchase means it now has full rights to develop glucose responsive insulins. https://www.bbc.co.uk/news/uk-england-bristol-45268904
-
Unique inflammation patterns observed in people with type 1 diabetes
US researchers have discovered that people with type 1 diabetes have unique inflammation patterns, which could help lead to treatments aimed at preventing complications. Long-term high blood sugar levels in people with type 1 diabetes appears to result in chronic inflammation, researchers say, which can impair organs, nerves and blood vessels. Scientists from Augusta University and Georgia Research Alliance Eminent Scholar in Genomic Medicine set about examining markers of inflammation in 89 people with diabetes-related kidney disease as well as 483 people with type 1 diabetes but without kidney problems. https://www.diabetes.co.uk/news/2018/mar/unique-inflammation-patterns-observed-in-people-with-type-1-diabetes-95983495.html